Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific

In brief

RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving busulfan and melphalan with or without antithymocyte globulin before transplant and cyclosporine with methylprednisolone or methotrexate after transplant may stop this from happening. PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant in treating young patients with relapsed or refractory solid tumors.

Key facts

Study ID
NCT00112645
Run by
Milton S. Hershey Medical Center
People needed
10
Starts
2005-04-01
Expected to finish
2011-02-01
Last updated by the study team
2013-07-18

Who can join

Age: any, up to 30. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.